HDAC modulation and cell death in the clinic

Experimental Cell Research

Volumn 318, Issue 11, 2012, Pages 1229-1244

  Dell'Aversana, Carmela ^a   Lepore, Ilaria ^b   Altucci, Lucia ^a,b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer; Clinical trials; Histone deacetylase inhibitors; Histone deacetylases

Indexed keywords

ABEXINOSTAT; APICIDIN; AZACITIDINE; BELINOSTAT; BENZAMIDE DERIVATIVE; CYCLOPEPTIDE; DACINOSTAT; DEPUDECIN; ENTINOSTAT; EPOXIDE; GIVINOSTAT; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; JNJ 16241199; MIDOSTAURIN; MOCETINOSTAT; PANOBINOSTAT; R 306465; RETINOIC ACID; ROMIDEPSIN; SB 939; SHORT CHAIN FATTY ACID; TETRAPEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVI 5008; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MESOTHELIOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84861679278     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.01.025     Document Type: Review

References (242)

1. Muller S., Filippakopoulos P., Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 2011, 13:e29.
2. Hagelkruys A., Sawicka A., Rennmayr M., Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb. Exp. Pharmacol. 2011, 206:13-37.
3. Altucci L., Clarke N., Nebbioso A., Scognamiglio A., Gronemeyer H. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int. J. Biochem. Cell Biol. 2005, 37(9):1752-1762.
4. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6(1):38-51.
5. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5(9):769-784.
6. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009, 280(2):125-133.
7. McKinsey T.A., Olson E.N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 2005, 115(3):538-546.
8. Verdin E., Dequiedt F., Kasler H. HDAC7 regulates apoptosis in developing thymocytes. Novartis Found Symp 2004.
9. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5(1):37-50.
10. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9(3):206-218.
11. Butler K.V., Kozikowski A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des. 2008, 14(6):505-528.
12. Hirschey M.D. Old enzymes, new tricks: sirtuins are NAD(+)-dependent de-acetylases. Cell Metab. 2011, 14(6):718-719.
13. Mutze K., Langer R., Becker K., Ott K., Novotny A., Luber B., Hapfelmeier A., Göttlicher M., Höfler H., Keller G. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 2010, 17(12):3336-3343.
14. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18(4):769-774.
15. Zhou W., Liang I.C., Yee N.S. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol. Ther. 2011, 11(7):659-670.
16. Hanigan C.L., Van Engeland M., De Bruine A.P., Wouters K.A., Weijenberg M.P., Eshleman J.R., Herman J.G. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008, 135(5). 1654-1664.e2.
17. Biçaku E., Marchion D.C., Schmitt M.L., Münster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signalling. Cancer Res. 2008, 68(5):1513-1519.
18. Thomas S., Munster P.N. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009, 280(2):184-191.
19. Marquard L., Poulsen C.B., Gjerdrum L.M., de Nully Brown P., Christensen I.J., Jensen P.B., Sehested M., Johansen P., Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54(6):688-698.
20. Adams H., Fritzsche F.R., Dirnhofer S., Kristiansen G., Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin. Ther. Targets 2010, 14(6):577-584.
21. Jin K.L., Pak J.H., Park J.Y., Choi W.H., Lee J.Y., Kim J.H., Nam J.H. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J. Gynecol. Oncol. 2008, 19(3):185-190.
22. Fritsche P., Seidler B., Schüler S., Schnieke A., Göttlicher M., Schmid R.M., Saur D., Schneider G Gut. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58(10):1399-1409.
23. Schneider G., Krämer O.H., Schmid R.M., Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J. Gastrointest. Cancer 2011, 42(2):85-92.
24. Weichert W., Röske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14(6):1669-1677.
25. Krishnan M., Singh A.B., Smith J.J., Sharma A., Chen X., Eschrich S., Yeatman T.J., Beauchamp R.D., Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene 2010, 29(2):305-312.
26. Oehme I., Deubzer H.E., Wegener D., Pickert D., Linke J.P., Hero B., Kopp-Schneider A., Westermann F., Ulrich S.M., von Deimling A., Fischer M., Witt O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 2009, 15(1):91-99.
27. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., Giardina C., Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28(14):1714-1724.
28. Zhang J., Yang Y., Yang T., Liu Y., Li A., Fu S., Wu M., Pan Z., Zhou W. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumorigenicity. Br. J. Cancer 2010, 103(8):1215-1220.
29. Roccaro A.M., Sacco A., Jia X., Azab A.K., Maiso P., Ngo H.T., Azab F., Runnels J., Quang P., Ghobrial I.M. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010, 116(9):1506-1514.
30. Sun Y., Sun D., Li F., Tian L., Li C., Li L., Lin R., Wang S. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 2007, 58(1):21-29.
31. Nakane K., Fujita Y., Terazawa R., Atsumi Y., Kato T., Nozawa Y., Deguchi T., Ito M. Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145cells. Int. J. Urol. 2011, 19(1):71-79.
32. Cea M., Soncini D., Fruscione F., Raffaghello L., Garuti A., Emionite L., Moran E., Magnone M., Zoppoli G., Reverberi D., Caffa I., Salis A., Cagnetta A., Bergamaschi M., Casciaro S., Pierri I., Damonte G., Ansaldi F., Gobbi M., Pistoia V., Ballestrero A., Patrone F., Bruzzone S., Nencioni A. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 2011, 6(7):e22739.
33. Kabra N., Li Z., Chen L., Li B., Zhang X., Wang C., Yeatman T., Coppola D., Chen J. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 2009, 284(27):18210-18217.
34. Peng L., Seto E. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb. Exp. Pharmacol. 2011, 206:39-56.
35. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 2010, 62(1):18-34.
36. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1(1):19-25.
37. Minucci S., Nervi C., Lo Coco F., Pelicci P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001, 20(24):3110-3115.
38. Lemercier C., Brocard M.P., Puvion-Dutilleul F., Kao H.Y., Albagli O., Khochbin S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem. 2002, 277(24):22045-22052.
39. Bereshchenko O.R., Gu W., Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 2002, 32(4):606-613.
40. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., Kasper L.H., Lerach S., Tang H., Ma J., Rossi D., Chadburn A., Murty V.V., Mullighan C.G., Gaidano G., Rabadan R., Brindle P.K., Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337):189-195.
41. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10(1):32-42.
42. Mottet D., Pirotte S., Lamour V., Hagedorn M., Javerzat S., Bikfalvi A., Bellahcène A., Verdin E., Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009, 28(2):243-256.
43. Wilson A.J., Byun D.S., Nasser S., Murray L.B., Ayyanar K., Arango D., Figueroa M., Melnick A., Kao G.D., Augenlicht L.H., Mariadason J.M. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol. Biol. Cell 2008, 19(10):4062-4075.
44. Wilting R.H., Yanover E., Heideman M.R., Jacobs H., Horner J., van der Torre J., DePinho R.A., Dannenberg J.H. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010, 29(15):2586-2597.
45. Eot-Houllier G., Fulcrand G., Watanabe Y., Magnaghi-Jaulin L., Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 2008, 22(19):2639-2644.
46. Elangovan S., Ramachandran S., Venkatesan N., Ananth S., Gnana-Prakasam J.P., Martin P.M., Browning D.D., Schoenlein P.V., Prasad P.D., Ganapathy V., Thangaraju M. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 2011, 71(21):6654-6664.
47. Sun Y., Sun D., Li F., Tian L., Li C., Li L., Lin R., Wang S. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 2007, 58(1):21-29.
48. Knight J.R., Milner J. SIRT1, metabolism and cancer. Curr. Opin. Oncol. 2012, 24(1):68-75.
49. Mottet D., Castronovo V. Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr. Cancer Drug Targets 2010, 10(8):898-913.
50. Geng H., Harvey C.T., Pittsenbarger J., Liu Q., Beer T.M., Xue C., Qian D.Z. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J. Biol. Chem. 2011, 286(44):38095-38102.
51. Mai A., Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41(1):199-213.
52. Humeniuk R., Mishra P.J., Bertino J.R., Banerjee D. Molecular targets for epigenetic therapy of cancer. Curr. Pharm. Biotechnol. 2009, 10(2):161-165.
53. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7(7):646-657.
54. Miller C.P., Singh M.M., Rivera-Del Valle N., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. Anticancer Agents Med. Chem. 2009, 9(1):99-108.
55. De Schutter H., Nuyts S. Radiosensitizing potential of epigenetic anticancer drugs. Biotechnology 2011, 2011:514261.
56. Sebova K., Fridrichova I. Epigenetic tools in potential anticancer therapy. Anticancer Drugs 2010, 21(6):565-577.
57. Lee J.H., Choy M.L., Ngo L., Foster S.S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(33):14639-14644.
58. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11(1):77-84.
59. Rawłuszko A.A., Krokowicz P., Jagodziński P.P. Butyrate induces expression of 17β-hydroxysteroid dehydrogenase type 1 in HT29 and SW707 colorectal cancer cells. DNA Cell Biol. 2011, 30(9):661-669.
60. Tang Y., Chen Y., Jiang H., Nie D. The role of short-chain fatty acids in orchestrating two types of programmed cell death in colon cancer. Autophagy 2011, 7(2):235-237.
61. Fauser J.K., Prisciandaro L.D., Cummins A.G., Howarth G.S. Fatty acids as potential adjunctive colorectal chemotherapeutic agents. Cancer Biol. Ther. 2011, 11(8):724-731.
62. Gore S.D., Carducci M.A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp. Opin. Investig. Drugs 2000, 9:2923-2934.
63. Scaglia F., Carter S., O'Brien W.E., Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol. Genet. Metab. 2004, 81(Suppl 1):S79-S85.
64. Samid D., Hudgins W.R., Shack S., Liu L., Prasanna P., Myers C.E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. 1997, 400A:501-505.
65. Witzig T.E., Timm M., Stenson M., Svingen P.A., Kaufmann S.H. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res. 2000, 6(2):681-692.
66. Lee B., Rhead W., Diaz G.A., Scharschmidt B.F., Mian A., Shchelochkov O., Marier J.F., Beliveau M., Mauney J., Dickinson K., Martinez A., Gargosky S., Mokhtarani M., Berry S.A. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol. Genet. Metab. 2010, 100(3):221-228.
67. Trojnar M.K., Wierzchowska-Cioch E., Krzyzanowski M., Jargiełło M., Czuczwar S.J. New generation of valproic acid. Pol. J. Pharmacol. 2004, 56(3):283-288.
68. Harwood A.J. Neurodevelopment and mood stabilizers. Curr. Mol. Med. 2003, 3(5):472-482.
69. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., Gelmetti V., Pascale S., Padula F., Petrucci M.T., Arcese W., Nervi C. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005, 65(4):1505-1513.
70. Kostrouchová M., Kostrouch Z., Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. (Praha) 2007, 53(2):37-49.
71. Michaelis M., Doerr H.W., Cinatl J. Valproic acid as anti-cancer drug. Curr. Pharm. Des. 2007, 13(33):3378-3393.
72. Mai A., Massa S., Pezzi R., Valente S., Loidl P., Brosch G. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 2005, 1(3):245-254.
73. Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., Koizumi K. A new antifungal antibiotic, trichostatin. J. Antibiot. (Tokyo) 1976, 29(1):1-6.
74. Tsuji N., Kobayashi M. Trichostatin C, a glucopyranosyl hydroxamate. J. Antibiot. (Tokyo) 1978, 31(10):939-944.
75. Vanhaecke T., Papeleu P., Elaut G., Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. 2004, 11(12):1629-1643.
76. Khan A.N., Gregorie C.J., Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 2008, 57(5):647-654.
77. Miyanaga A., Gemma A., Noro R., Kataoka K., Matsuda K., Nara M., Okano T., Seike M., Yoshimura A., Kawakami A., Uesaka H., Nakae H., Kudoh S. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol. Cancer Ther. 2008, 7(7):1923-1930.
78. Zhang F., Zhang T., Teng Z.H., Zhang R., Wang J.B., Mei Q.B. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol. Ther. 2009, 8(9):823-831.
79. Hu J., Colburn N.H. Histone deacetylase inhibition downregulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol. Cancer Res. 2005, 3(2):100-109.
80. Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 2008, 615:261-298.
81. Kiyokawa H., Richon V.M., Venta-Perez G., Rifkind R.A., Marks P.A. Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(14):6746-6750.
82. Andreeff M., Stone R., Michaeli J., Young C.W., Tong W.P., Sogoloff H., Ervin T., Kufe D., Rifkind R.A., Marks P.A. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992, 80(10):2604-2609.
83. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(6):3003-3007.
84. Khan O., La Thangue N.B. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 2008, 5(12):714-726.
85. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26(9):1351-1356.
86. Zhang C., Richon V., Ni X., Talpur R., Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 2005, 125(5):1045-1052.
87. Huang L., Sowa Y., Sakai T., Pardee A.B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000, 19(50):5712-5719.
88. Li D., Marchenko N.D., Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011, 18(12):1904-1913. 10.1038/cdd.2011.71.
89. Pontiki E., Hadjipavlou-Litina D. Histone deacetylase inhibitors (HDACIs). Structure -activity relationships: history and new QSAR perspectives. Med. Res. Rev. 2012, 32(1):1-165.
90. Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Hess. Int. J. Biochem. Cell. Biol. 2007, 39(7-8):1388-1405.
91. Boumber Y., Younes A., Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin. Investig. Drugs 2011, 20(6):823-829.
92. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., Liu J., Lu A.H., Zhou N.Z., Robert M.F., Gillespie J., Wang J.J., Ste-Croix H., Rahil J., Lefebvre S., Moradei O., Delorme D., Macleod A.R., Besterman J.M., Li Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2008, 7(4):759-768.
93. Brosch G., Ransom R., Lechner T., Walton J.D., Loidl P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell. 1995, 7(11):1941-1950.
94. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(1):87-92.
95. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62(17):4916-4921.
96. Bertino E.M., Otterson G.A. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs 2011, 20(8):1151-1158. 10.1517/13543784.2011.594437.
97. Sato N., Ohta T., Kitagawa H., Kayahara M., Ninomiya I., Fushida S., Fujimura T., Nishimura G., Shimizu K., Miwa K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol. 2004, 24(3):679-685.
98. Vanoosten R.L., Moore J.M., Ludwig A.T., Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 2005, 11(4):542-552.
99. Ahn M.Y., Ahn S.G., Yoon J.H. Apicidin, a histone deacetylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol. 2011, 47(11):1032-1038.
100. Im J.Y., Park H., Kang K.W., Choi W.S., Kim H.S. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and -negative human breast cancer cells. Chem. Biol. Interact. 2008, 172(3):235-244.
101. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., Kim M.R., Kim K.W., Kim W.B., Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Kim Biochem. Biophys. Res. Commun. 2004, 315(4):964-970.
102. Oikawa T., Onozawa C., Inose M., Sasaki M. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol. Pharm. Bull. 1995, 18(9):1305-1307.
103. García J., Franci G., Pereira R., Benedetti R., Nebbioso A., Rodríguez-Barrios F., Gronemeyer H., Altucci L., de Lera A.R. Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. Bioorg. Med. Chem. 2011, 19(12):3637-3649.
104. Piña I.C., Gautschi J.T., Wang G.Y., Sanders M.L., Schmitz F.J., France D., Cornell-Kennon S., Sambucetti L.C., Remiszewski S.W., Perez L.B., Bair K.W., Crews P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68(10):3866-3873.
105. Baud M.G., Leiser T., Meyer-Almes F.J., Fuchter M.J. New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation. Org. Biomol. Chem. 2011, 9(3):659-662.
106. Ahn M.Y., Jung J.H., Na Y.J., Kim H.S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 2008, 108(1):27-33.
107. Park Y., Liu Y., Hong J., Lee C.O., Cho H., Kim D.K., Im K.S., Jung J.H. New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J. Nat. Prod. 2003, 66(11):1495-1498.
108. Kim D., Lee I.S., Jung J.H., Lee C.O., Choi S.U. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer. Res. 1999, 19(5B):4085-4090.
109. Nebbioso A., Pereira R., Khanwalkar H., Matarese F., García-Rodríguez J., Miceli M., Logie C., Kedinger V., Ferrara F., Stunnenberg H.G., de Lera A.R., Gronemeyer H., Altucci L. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor, UVI5008. Mol. Cancer Ther. 2011, 10(12):2394-2404.
110. Venugopal B., Evans T.R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 2011, 18(11):1658-1671.
111. Zhao X., Yang W., Shi C., Ma W., Liu J., Wang Y., Jiang G. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumor Biol. 2011, 32(2):335-346.
112. Sun P.C., Tzao C., Chen B.H., Liu C.W., Yu C.P., Jin J.S. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J. Biomed. Sci. 2010, 17:76-85.
113. Panicker J., Li Z., McMahon C., Sizer C., Steadman K., Piekarz R., Bates S.E., Thiele C.J. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle 2010, 9(9):1830-1838.
114. Takai N., Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 2007, 14(24):2548-2553.
115. Mork C.N., Faller D.V., Spanjaard R.A. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr. Pharm. Des. 2005, 11(9):1091-1104.
116. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7(7):646-657.
117. Mei S., Ho A.D., Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. Int. J. Oncol. 2004, 25(6):1509-1519.
118. Ocker M., Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 2007, 39(7-8):1367-1374.
119. Hitomi T., Matsuzaki Y., Yokota T., Takaoka Y., Sakai T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS 2003, 554(3):347-350.
120. Yokota T., Matsuzaki Y., Sakai T. Trichostatin A activates p18INK4c gene: differential activation and cooperation with p19INK4d gene. FEBS 2004, 574(1-3):171-175.
121. Mitsiades C.S., Poulaki V., McMullan C., Negri J., Fanourakis G., Goudopoulou A., Richon V.M., Marks P.A., Mitsiades N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin. Cancer Res. 2005, 11(10):3958-3965.
122. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 2005, 33(1):53-61.
123. Brodska B., Otevrelova P., Kalousek I. Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death. Cell Biochem. Funct. 2009, 27(3):167-175.
124. Hirsch C.L., Smith-Windsor E.L., Bonham K. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int. J. Cancer 2006, 118(3):547-554.
125. Hsu Y.F., Sheu J.R., Hsiao G., Lin C.H., Chang T.H., Chiu P.T., Wang C.Y., Hsu M.J. p53 in trichostatin A induced C6 glioma cell death. Biochim. Biophys. Acta 2011, 1810(5):504-513.
126. Zhuang Z.G., Fei F., Chen Y., Jin W. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol. Sin. 2008, 29(12):1459-1466.
127. 2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes. J. Cell. Mol. Med. 2009, 13(9B):3632-3643.
128. Chinnaiyan P., Varambally S., Tomlins S.A., Ray S., Huang S., Chinnaiyan A.M., Harari P.M. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer 2006, 118(4):1041-1050.
129. Joo Noh Eun, Lim Dae-Sik, Jeong Gajin, Lee Jong-Soo An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem. Biophys. Res. Commun. 2009, 378(3):326-331.
130. Ma Y., Cai S., Lu Q., Lu X., Jiang Q., Zhou J., Zhang C. Inhibition of protein deacetylation by trichostatin A impairs microtubule-kinetochore attachment. Cell. Mol. Life Sci. 2008, 65(19):3100-3109.
131. Dowling M., Voong K.R., Kim M., Keutmann M.K., Harris E., Kao G.D. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther. 2005, 4(2):197-206.
132. Park Jung-Hyun, Jong Hyun-Soon, Gyun Kim Sang, Jung Yeonjoo, Lee Keun-Wook, Lee Ju-Hee, Kim Dae-Kee, Bang Yung-Jue, Kim Tae-You Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J. Mol. Med. (Berl) 2008, 86(1):117-128.
133. Zhang X., Zhang Z., Chen G., Zhao M., Wang D., Zhang X., Du Z., Xu Y., Yu X. FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42(10):677-687.
134. Robbins A.R., Jablonski S.A., Yen T.J., Yoda K., Robey R., Bates S.E., Sackett D.L. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005, 4(5):717-726.
135. Zhang X.H., Rao M., Loprieato J.A., Hong J.A., Zhao M., Chen G.Z., Humphries A.E., Nguyen D.M., Trepel J.B., Yu X., Schrump D.S. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol. Ther. 2008, 7(9):1388-1397.
136. Cheriyath V., Kuhns M.A., Kalaycio M.E., Borden E.C. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br. J. Cancer 2011, 104(6):957-967.
137. Pérez-Perarnau A., Coll-Mulet L., Rubio-Patiño C., Iglesias-Serret D., Cosialls A.M., González-Gironès D.M., de Frias M., de Sevilla A.F., de la Banda E., Pons G., Gil J. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 2011, 6(10).
138. Altmann A., Eisenhut M., Bauder-Wüst U., Markert A., Askoxylakis V., Hess-Stumpp H., Haberkorn U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(12):2286-2297.
139. Brazelle W., Kreahling J.M., Gemmer J., Ma Y., Cress W.D., Haura E., Altiok S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 2010, 5(12):e14335.
140. Qiu J., Gao Z., Shima H. Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. Oncol. Rep. 2012, 27(1):160-167. 10.3892/or.2011.1470.
141. Park J.H., Ahn M.Y., Kim T.H., Yoon S., Kang K.W., Lee J., Moon H.R., Jung J.H., Chung H.Y., Kim H.S. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest. New Drugs 2011, [Epub ahead of print].
142. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23(37):6261-6271.
143. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11(1):71-76.
144. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39:1388-1405.
145. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11(1):77-84.
146. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004, 11(Suppl 2):S193-S206.
147. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9(3):231-241.
148. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 2011, 21(1):92-101.
149. Dickinson M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest. New Drugs 2010, 28(Suppl1):S3-S20.
150. Hwang J.J., Kim Y.S., Kim M.J., Kim D.E., Jeong I.G., Kim C.S. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J. Urol. 2010, 184(6):2557-2564.
151. El-Khoury V., Moussay E., Janji B., Palissot V., Aouali N., Brons N.H., Van Moer K., Pierson S., Van Dyck E., Berchem G. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol. Cancer Ther. 2010, 9(5):1349-1360.
152. Fandy T.E., Srivastava R.K. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother. Pharmacol. 2006, 58(4):471-477.
153. Khan S.B., Maududi T., Barton K., Ayers J., Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol. 2004, 125:156-161.
154. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8(2):132-140.
155. Miller C.P., Singh M.M., Rivera-Del Valle N., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 514261. (2011).
156. Brodská B., Holoubek A. Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxid. Med. Cell Longev. 2011, 2011:253529.
157. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
158. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
159. Engesæter B.O., Sathermugathevan M., Hellenes T., Engebråten O., Holm R., Flørenes V.A., Mælandsmo G.M. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol. Ther. 2011, 12(1):47-58.
160. Mori T., Doi R., Kida A., Nagai K., Kami K., Ito D., Toyoda E., Kawaguchi Y., Uemoto S. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 2007, 142(2):281-286.
161. Arlt A., Müerköster S.S., Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2010, [Epub ahead of print].
162. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell. Biol. 2005, 25(13):5429-5444.
163. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(52):18030-18035.
164. Ahn M.Y., Ahn S.G., Yoon J.H. Apicidin, a histone deacetylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol. 2011, 47(11):1032-1038.
165. Yamamoto S., Tanaka K., Sakimura R., Okada T., Nakamura T., Li Y., Takasaki M., Nakabeppu Y., Iwamoto Y. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer. Res. 2008, 28(3A):1585-1591.
166. Hrzenjak A., Kremser M.L., Strohmeier B., Moinfar F., Zatloukal K., Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J. Pathol. 2008, 216(4):495-504.
167. Muscolini M., Cianfrocca R., Sajeva A., Mozzetti S., Ferrandina G., Costanzo A., Tuosto L. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol. Cancer Ther. 2008, 7(6):1410-1419.
168. Li J., Liu R., Lei Y., Wang K., Lau Q.C., Xie N., Zhou S., Nie C., Chen L., Wei Y., Huang C. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 2010, 6(6):711-724.
169. Premkumar D.R., Jane E.P., Agostino N.R., Didomenico J.D., Pollack I.F. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol. Carcinog. 2011, [Epub ahead of print], doi:10.1002/mc.21835.
170. Wilson A.J., Holson E., Wagner F., Zhang Y.L., Fass D.M., Haggarty S.J., Bhaskara S., Hiebert S.W., Schreiber S.L., Khabele D. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol. Ther. 2011, 12(6):484-493. doi:10.4161/cbt.12.6.15956.
171. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8(4):286-298.
172. Fraga M.F., Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005, 4(10):1377-1381.
173. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25(1):84-90.
174. Bereshchenko O.R., Gu W., Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 2002, 32(4):606-613.
175. Inoue T., Hiratsuka M., Osaki M., Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007, 6(9):1011-1018.
176. Olmos Y., Brosens J.J., Lam E.W. Interplay between SIRT proteins and tumor suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist. Updat. 2011, 14(1):35-44.
177. Bouras T., Fu M., Sauve A.A., Wang F., Quong A.A., Perkins N.D., Hay R.T., Gu W., Pestell R.G. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J. Biol. Chem. 2005, 280(11):10264-10276.
178. Sundaresan N.R., Samant S.A., Pillai V.B., Rajamohan S.B., Gupta M.P. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell. Biol. 2008, 28(20):6384-6401.
179. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23(12):2369-2380.
180. Fu M., Liu M., Sauve A.A., Jiao X., Zhang X., Wu X., Powell M.J., Yang T., Gu W., Avantaggiati M.L., Pattabiraman N., Pestell T.G., Wang F., Quong A.A., Wang C., Pestell R.G. Hormonal control of androgen receptor function through SIRT1. Mol. Cell. Biol. 2006, 26(21):8122-8135.
181. Munster P.N., Marchion D., Thomas S., Egorin M., Minton S., Springett G., Lee J.H., Simon G., Chiappori A., Sullivan D., Daud A. Phase I trial of vorinostat and doxorubicin in solid tumors: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101(7):1044-1050.
182. Weichert W., Röske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14(6):1669-1677.
183. Mutze K., Langer R., Becker K., Ott K., Novotny A., Luber B., Hapfelmeier A., Göttlicher M., Höfler H., Keller G. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 2010, 17(12):3336-3343.
184. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., Li L., Gooden F., Korenchuk S., Hou X.S., Harrington E.A., Randolph S., Reilly J.F., Ware C.M., Kadin M.E., Frankel S.R., Richon V.M. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008, 68(10):3785-3794.
185. Chen L., Shinde U., Ortolan T.G., Madura K. Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep. 2001, 2(10):933-938.
186. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., Bernards R., La Thangue N.B. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009, 15(1):57-66.
187. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105(4):1768-1776.
188. Rahmani M., Reese E., Dai Y., Bauer C., Kramer L.B., Huang M., Jove R., Dent P., Grant S. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with downregulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 2005, 67(4):1166-1176.
189. Kircher B., Schumacher P., Petzer A., Hoflehner E., Haun M., Wolf A.M., Nachbaur D., Gastl G. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur. J. Haematol. 2009, 83(1):48-56.
190. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63(16):5126-5135.
191. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., Czarnik A.C., Payne S.G., Spiegel S., Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004, 64(7):2590-2600.
192. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., Wang H.G., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003, 2(10):971-984.
193. Bali P., George P., Cohen P., Tao J., Guo F., Sigua C., Vishvanath A., Scuto A., Annavarapu S., Fiskus W., Moscinski L., Atadja P., Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 2004, 10(15):4991-4997.
194. Yu C., Rahmani M., Conrad D., Subler M., Dent P., Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003, 102(10):3765-3774.
195. Shankar S., Singh T.R., Fandy T.E., Luetrakul T., Ross D.D., Srivastava R.K. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int. J. Mol. Med. 2005, 16(6):1125-1138.
196. Singh T.R., Shankar S., Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24(29):4609-4623.
197. Voso M.T., Santini V., Finelli C., Musto P., Pogliani E., Angelucci E., Fioritoni G., Alimena G., Maurillo L., Cortelezzi A., Buccisano F., Gobbi M., Borin L., Di Tucci A., Zini G., Petti M.C., Martinelli G., Fabiani E., Fazi P., Vignetti M., Piciocchi A., Liso V., Amadori S., Leone G. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin. Cancer Res. 2009, 15(15):5002-5007.
198. Raffoux E., Cras A., Recher C., Boëlle P.Y., de Labarthe A., Turlure P., Marolleau J.P., Reman O., Gardin C., Victor M., Maury S., Rousselot P., Malfuson J.V., Maarek O., Daniel M.T., Fenaux P., Degos L., Chomienne C., Chevret S., Dombret H. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1(1):34-42.
199. Daud A.I., Dawson J., DeConti R.C., Bicaku E., Marchion D., Bastien S., Hausheer F.A., Lush R., Neuger A., Sullivan D.M., Munster P.N. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin. Cancer Res. 2009, 15(7):2479-2487.
200. Rocca A., Minucci S., Tosti G., Croci D., Contegno F., Ballarini M., Nolè F., Munzone E., Salmaggi A., Goldhirsch A., Pelicci P.G., Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 2009, 100(1):28-36.
201. Munster P., Marchion D., Bicaku E., Lacevic M., Kim J., Centeno B., Daud A., Neuger A., Minton S., Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009, 15(7):2488-2496.
202. Schaefer E.W., Loaiza-Bonilla A., Juckett M., DiPersio J.F., Roy V., Slack J., Wu W., Laumann K., Espinoza-Delgado I., Gore S.D. Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009, 94(10):1375-1382.
203. Kirschbaum M.H., Goldman B.H., Zain J.M., Cook J.R., Rimsza L.M., Forman S.J., Fisher R.I. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk. Lymphoma 2011, 53(2):259-262.
204. Kadia T.M., Yang H., Ferrajoli A., Maddipotti S., Schroeder C., Madden T.L., Holleran J.L., Egorin M.J., Ravandi F., Thomas D.A., Newsome W., Sanchez-Gonzalez B., Zwiebel J.A., Espinoza-Delgado I., Kantarjian H.M., Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br. J. Haematol. 2010, 150(1):72-82.
205. Mazumder A., Vesole D.H., Jagannath S. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. Clin. Lymphoma Myeloma Leuk. 2010, 10(2):149-151.
206. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., Baer M.R., Holleran J.L., Egorin M.J., Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. S. Clin. Cancer Res. 2009, 15(16):5250-5257.
207. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., Sun L., Ricker J., Rizvi S., Oerth C., Atkins B., Fearen I., Anderson K., Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 2008, 49(3):502-507.
208. Siegel D., Hussein M., Belani C., Robert F., Galanis E., Richon V.M., Garcia-Vargas J., Sanz-Rodriguez C., Rizvi S. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2009, 2:31.
209. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., Randolph S.S., Hardwick J.S., Reilly J.F., Chen C., Ricker J.L., Secrist J.P., Richon V.M., Frankel S.R., Kantarjian H.M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111(3):1060-1066.
210. Bradley D., Rathkopf D., Dunn R., Stadler W.M., Liu G., Smith D.C., Pili R., Zwiebel J., Scher H., Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009, 115(23):5541-5549.
211. Millward M., Price T., Townsend A., Sweeney C., Spencer A., Sukumaran S., Longenecker A., Lee L., Lay A., Sharma G., Gemmill R.M., Drabkin H.A., Lloyd G.K., Neuteboom S.T., McConkey D.J., Palladino M.A., Spear M.A. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs 2011, [Epub ahead of print].
212. Ramalingam S.S., Maitland M.L., Frankel P., Argiris A.E., Koczywas M., Gitlitz B., Thomas S., Espinoza-Delgado I., Vokes E.E., Gandara D.R., Belani C.P. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28(1):56-62.
213. Vansteenkiste J., Van Cutsem E., Dumez H., Chen C., Ricker J.L., Randolph S.S., Schöffski P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 2008, 26(5):483-488.
214. Zhang C., Richon V., Ni X., Talpur R., Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 2005, 125(5):1045-1052.
215. Wozniak M.B., Villuendas R., Bischoff J.R., Aparicio C.B., Martínez Leal J.F., de La Cueva P., Rodriguez M.E., Herreros B., Martin-Perez D., Longo M.I., Herrera M., Piris M.A., Ortiz-Romero P.L. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010, 95(4):613-621.
216. Dickinson M., Ritchie D., DeAngelo D.J., Spencer A., Ottmann O.G., Fischer T., Bhalla K.N., Liu A., Parker K., Scott J.W., Bishton M., Prince H.M. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br. J. Haematol. 2009, 147(1):97-101.
217. Dimicoli S., Jabbour E., Borthakur G., Kadia T., Estrov Z., Yang H., Kelly M., Pierce S., Kantarjian H., Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am. J. Hematol. 2011, 87(1):127-129.
218. Ocio E.M., Vilanova D., Atadja P., Maiso P., Crusoe E., Fernández-Lázaro D., Garayoa M., San-Segundo L., Hernández-Iglesias T., de Alava E., Shao W., Yao Y.M., Pandiella A., San-Miguel J.F. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95(5):794-803.
219. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12(15):4628-4635.
220. Hainsworth J.D., Infante J.R., Spigel D.R., Arrowsmith E.R., Boccia R.V., Burris H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011, 29(7):451-455.
221. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., Buhl-Jensen P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 2008, 81(3):170-176.
222. Ramalingam S.S., Belani C.P., Ruel C., Frankel P., Gitlitz B., Koczywas M., Espinoza-Delgado I., Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 2009, 4(1):97-101.
223. Mackay H.J., Hirte H., Colgan T., Covens A., MacAlpine K., Grenci P., Wang L., Mason J., Pham P.A., Tsao M.S., Pan J., Zwiebel J., Oza A.M. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors. Eur. J. Cancer 2010, 46(9):1573-1579.
224. Rambaldi A., Dellacasa C.M., Finazzi G., Carobbio A., Ferrari M.L., Guglielmelli P., Gattoni E., Salmoiraghi S., Finazzi M.C., Di Tollo S., D'Urzo C., Vannucchi A.M., Barosi G., Barbui T. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br. J. Haematol. 2010, 150(4):446-455.
225. Yang C., Choy E., Hornicek F.J., Wood K.B., Schwab J.H., Liu X., Mankin H., Duan Z. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer. Res. 2011, 31(4):1115-1123.
226. Younes A., Oki Y., Bociek R.G., Kuruvilla J., Fanale M., Neelapu S., Copeland A., Buglio D., Galal A., Besterman J., Li Z., Drouin M., Patterson T., Ward M.R., Paulus J.K., Ji Y., Medeiros L.J., Martell R.E. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011, 12(13):1222-1228.
227. Blum K.A., Advani A., Fernandez L., Van Der Jagt R., Brandwein J., Kambhampati S., Kassis J., Davis M., Bonfils C., Dubay M., Dumouchel J., Drouin M., Lucas D.M., Martell R.E., Byrd J.C. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 2009, 147(4):507-514.
228. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W.M., Miller W.H., Rousseau C., Kalita A., Bonfils C., Dubay M., Patterson T.A., Li Z., Besterman J.M., Reid G., Laille E., Martell R.E., Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112(4):981-989.
229. Siu L.L., Pili R., Duran I., Messersmith W.A., Chen E.X., Sullivan R., MacLean M., King S., Brown S., Reid G.K., Li Z., Kalita A.M., Laille E.J., Besterman J.M., Martell R.E., Carducci M.A. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26(12):1940-1947.
230. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., Yang A.S., Aucott T., Dauses T., Odchimar-Reissig R., Licht J., McConnell M.J., Nasrallah C., Kim M.K., Zhang W., Sun Y., Murgo A., Espinoza-Delgado I., Oteiza K., Owoeye I., Silverman L.R., Gore S.D., Carraway H.E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114(13):2764-2773.
231. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., Tidwell M.L., Greer J., Chung E.J., Lee M.J., Gore S.D., Sausville E.A., Zwiebel J., Karp J.E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109(7):2781-2790.
232. Kummar S., Gutierrez M., Gardner E.R., Donovan E., Hwang K., Chung E.J., Lee M.J., Maynard K., Kalnitskiy M., Chen A., Melillo G., Ryan Q.C., Conley B., Figg W.D., Trepel J.B., Zwiebel J., Doroshow J.H., Murgo A.J. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 2007, 13(18 Pt 1):5411-5417.
233. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23(17):3912-3922.
234. L, Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2008, 14(14):4517-4525.
235. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009, 45(11):787-795.
236. Hymes K.B. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. Clin. Lymphoma Myeloma Leuk. 2010, 10(2):98-109.
237. Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S.L., Kirschbaum M.H., Zain J., Prince H.M., Leonard J.P., Geskin L.J., Reeder C., Joske D., Figg W.D., Gardner E.R., Steinberg S.M., Jaffe E.S., Stetler-Stevenson M., Lade S., Fojo A.T., Bates S.E. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 2009, 27(32):5410-5417.
238. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., Jaffe E.S., Ling A., Turner M., Peer C.J., Figg W.D., Steinberg S.M., Smith S., Joske D., Lewis I., Hutchins L., Craig M., Fojo A.T., Wright J.J., Bates S.E. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117(22):5827-5834.
239. Harrison S.J., Quach H., Link E., Seymour J.F., Ritchie D.S., Ruell S., Dean J., Januszewicz H., Johnstone R., Neeson P., Dickinson M., Nichols J., Prince H.M. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011, 118(24):6274-6283.
240. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., Chen-Kiang S., Sparano J.A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117(2):336-342.
241. Molife L.R., Attard G., Fong P.C., Karavasilis V., Reid A.H., Patterson S., Riggs C.E., Higano C., Stadler W.M., McCulloch W., Dearnaley D., Parker C., de Bono J.S. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 2010, 21(1):109-113.
242. Whitehead R.P., Rankin C., Hoff P.M., Gold P.J., Billingsley K.G., Chapman R.A., Wong L., Ward J.H., Abbruzzese J.L., Blanke C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest. New Drugs 2009, 27(5):469-475.